Cognition Therapeutics

Cognition Therapeutics is a clinical-stage biopharmaceutical company leveraging two decades of research to deliver treatments for neurodegenerative diseases.

[Cognition Therapeutics @CogRx]

September is World Alzheimer’s Month - an internationally coordinated campaign to raise awareness and reduce the stigma of dementias like #Alzheimers disease, #dementia with Lewy bodies, and others. Symptoms of memory loss, agitation, #hallucinations are common yet seldom discussed.

The focus of this year's #WorldAlzMonth is to reduce stigma, increase education, and empower people to discuss their symptoms with their care partners and physicians so everyone can receive an accurate and timely diagnosis.

Take a moment to learn more about dementia today. https://t.co/Tqmk5Zx27s

#EarlyDiagnosisMatters #DementiaDiagnosisMatters #DementiawithLewyBodies #ENDAlz #LewyStrong

[Cognition Therapeutics @CogRx]

Great work from Drs. Mary Hamby and Gary Look as well as the team at PROTEROS biostructures GmbH on elucidating the crystal structure of #zervimesine (CT1812) and illustrating it interaction with neuronal receptors. Read more at ACS Publications: https://t.co/RWwOc0z8fZ.

[Cognition Therapeutics @CogRx]

It's time to rethink neurodegenerative disease.

For decades, diseases like #Alzheimers, #Parkinsons, and #DLB have been diagnosed based on clinical symptoms. However, emerging evidence suggests these aren't discrete disorders but rather points on a complex and interconnected continuum.

In a new article for @NeuroAdvisor, our chief medical officer, Dr. Anthony Caggiano, explores the shift towards a "biology-first" approach.

Read the full article to learn more about the future of neurodegenerative care: https://t.co/JRKcMc4PCf

#Neurology #BiotechnologyInnovation #AlzheimersDisease #Dementia

[Cognition Therapeutics @CogRx]

Today we presented a poster at #AAIC26 providing support for a Phase 3 program in individuals with #dementia with Lewy bodies (DLB) who experience #psychosis. Learn more about #DLBPsychosis and the neuropsychiatric findings from the #zervimesine Phase 2 'SHIMMER' study by viewing a copy of the poster on our publications webpage: https://t.co/9ZXWWY38Pf.

#BiotechInnovation #ClinicalResearch #DementiaWithLewyBodies #LewyBodyDementia #DementiaPsychosis #LewyStrong #Hallucinations #Delusions

[Cognition Therapeutics @CogRx]

It has been great to catch up with #Pentara and our other collaborators and friends at #AAIC26 in London!

#Alzheimersdisease #dementia #AlzheimersResearch #ClinicalTrials #Biostatistics #RegulatoryAffairs

[Cognition Therapeutics @CogRx]

$CGTX CEO, Lisa Ricciardi will join #BRileySecurities analyst, Dr. William Wood for an in-person fireside chat during their Mind, Muscle & Vision Summit. #Pressrelease: https://t.co/R1dav3ffez The event is being conducted on July 16 at the Intercontinental Boston Hotel.

#BiotechInnovation #ClinicalResearch #DementiaWithLewyBodies #DLBPsychosis #AlzheimersDisaease #InvestorConference #ThoughtLeadership #BiotechInvesting

[Cognition Therapeutics @CogRx]

As we mark Alzheimer's & Brain Awareness Month (#ABAM) this June, it's important to remember that dementia is not a single disease.

#Alzheimers disease, #dementia with Lewy bodies (DLB), vascular dementia, and frontotemporal dementia all present differently - and they all respond differently to treatment.

Interventions appropriate for one type of dementia can be ineffective or harmful to people with another type. An accurate diagnosis is important to ensure safe, appropriate care. Learn more at https://t.co/cIFr4R5lBx

#DementiaAwareness #EndALZ #DementiaSupport

[Cognition Therapeutics @CogRx]

$CGTX received written feedback from the U.S. #FDA following their meeting in May. Read the press release here: https://t.co/PQJnkjAP8w

The FDA agreed that #psychosis associated with #dementia with Lewy bodies (DLB) could be an approvable outcome. The agency also reached alignment with the Company on key aspects of a pivotal trial for #zervimesine, which is expected to begin in mid-2027.

#BiotechInnovation #ClinicalResearch #DementiaWithLewyBodies #LewyBodyDementia #DementiaPsychosis #DLBPsychosis #DementiaSupport #LewyStrong #Hallucinations #Delusions

[Cognition Therapeutics @CogRx]

June is Alzheimer's and Brain Awareness Month. Within this month, June 21st - the summer solstice - has long been the official awareness day uniting researchers, patients, caregivers and families impacted by #Alzheimers.

On this day, as on every day, we stand with our colleagues in the pharmaceutical industry, physicians, patients and caregivers to recognize the struggle of Alzheimer’s disease.

Only together, can we #ENDALZ.

[Cognition Therapeutics @CogRx]

What's next for Cognition Therapeutics? $CGTX CEO, Lisa Ricciardi discusses the company's recent interactions with the #FDA and plans to advance #zervimesine for #DLBPsychosis in this video interview with Fierce Biotech: https://t.co/SMxEdUZBfs

#DementiaResearch #BrainHealth #LewyStrong #DementiawithLewyBodies

[Cognition Therapeutics @CogRx]

$CGTX CEO, will join H.C. Wainwright's Dr. Ram Selvaraju for a virtual fireside chat during their Neuro Perspectives Expert Summit. The virtual fireside will be available on demand beginning at 7:00am ET on June 15th. Find a link to the live and archived presentation on the Cognition Therapeutics IR webpage: https://t.co/pZ3SQXutRg

#HCWConference #InvestorConference #BiotechInvesting #DementiaWithLewyBodies #DLBPsychosis #DLB

[Cognition Therapeutics @CogRx]

$CGTX CEO, Lisa Ricciardi, will present at 1:25 p.m. ET today at the 2026 @Jefferies Global Healthcare Conference, which is being held at the Marriott Marquis in New York City. Find a link to the live and archived presentation on the Cognition Therapeutics IR webpage: https://t.co/pZ3SQXutRg

#JefferiesHealthcare #InvestorConference #ThoughtLeadership #BiotechInvesting #DementiaWithLewyBodies #DLBPsychosis #DLB

[Cognition Therapeutics @CogRx]

See $CGTX CMO, Anthony Caggiano, MD, PhD discuss Phase 2 #DLB results in an interview with Psychiatric Times: https://t.co/MTpBK6hIsK

"The strongest data that we had were within the behavioral symptoms - things like hallucinations, delusions, anxiety, agitation and so forth. What we saw was that when you treat these people with a placebo through over the course of the six months of the trial, their symptoms got worse and worse. Whereas when we treated them with zervimesine, their symptoms were really quite stable."

#BiotechInnovation #ClinicalResearch #DementiaWithLewyBodies #LewyBodyDementia #Dementia #DLBPsychosis #DementiaSupport #LewyStrong #Psychosis #Hallucinations #Delusions

[Cognition Therapeutics @CogRx]

Psychosis symptoms - #hallucinations and #delusions - are common in people living with DLB. $CGTX CEO, Lisa Ricciardi discusses the debilitating nature of DLB #psychosis and more in this video interview with Fierce Biotech: https://t.co/xQRxhpz56O

#DementiaResearch #BrainHealth #LewyStrong #DementiawithLewyBodies #LewyBodyDementia

[Cognition Therapeutics @CogRx]

Yesterday the $CGTX team had a productive meeting with the FDA to review results from the Phase 2 study of #zervimesine (CT1812) and discuss the design and endpoints of a registrational study in #dementia with Lewy bodies (#DLB) patients with #psychosis. #Pressrelease: https://t.co/Ylegj9BqTW

#BiotechInnovation #ClinicalResearch #DementiaWithLewyBodies #LewyBodyDementia #DementiaPsychosis #DLBPsychosis #LewyStrong #Hallucinations #Delusions

[Cognition Therapeutics @CogRx]

May 20th is #ClinicalTrialsDay (#CTD2026), an annual event designed to honor the people that move research forward. Learn more: https://t.co/TvFp83DU34

At $CGTX, we have an amazing team of clinical operations professionals. But to us, the real heroes are the patients and their caregivers. It is only due to their trust in us that we’ve been able to advance #zervimesine.

#BiotechInnovation #ClinicalTrials #ClinicalResearch #DementiaResearch

[Cognition Therapeutics @CogRx]

Welcome to #AskCGTX. In this video, $CGTX CEO, Lisa Ricciardi explains the company's decision to advance #zervimesine for DLB #psychosis. She highlights favorable Phase 2 trial results and the overwhelming unmet need for people living with #DLB

#Lewybodydementia #DementiawithLewyBodies #LewyStrong #BiotechInnovation #BrainHealth #AskMeAnything #DYK

[Cognition Therapeutics @CogRx]

Join the @LBDAssoc for this important webinar on off-label use of medications in people with dementia with Lewy bodies (#DLB) and Parkinson's disease dementia (PDD).

People living with Lewy body dementias may have symptoms common to other conditions, but many drugs approved to treat other diseases cannot be tolerated by people living with LBDs. Register and learn more: https://t.co/xwvBJNRTW0.

#Lewystrong #DementiawithLewyBodies #ParkinsonsDiseaseDementia

[Lewy Body Dementia Association @LBDAssoc]

Join Dr. Matt Barrett on Wednesday, May 20 at 1:00pm ET for “Making Sense of Medications in Lewy Body Dementia.” You will learn about commonly used medications in LBD, potential side effects and which medications may need to be avoided.

Register today at https://t.co/3e0EKlKVxZ

[Cognition Therapeutics @CogRx]

Thanks to the @FierceBiotech team for the opportunity to discuss our clinical development programs for #zervimesine in #Alzheimers and #DLB: https://t.co/xQRxhpzCWm.

Listen to the discussion as Ms. Ricciardi recaps the Phase 2 results in #dementia with Lewy bodies and Cognition's plans to focus on DLB psychosis.

#DementiawithLewyBodies #LewyStrong #DementiaSupport #DementiaResearch #BrainHealth #BiotechInnovation

[Cognition Therapeutics @CogRx]

$CGTX announced a second philanthropic donation to support the ongoing expanded access program for people with #dementia with Lewy bodies: https://t.co/NFZZ7mLLbq

#Zervimesine #BiotechInnovation #ClinicalResearch #DementiaWithLewyBodies #LewyBodyDementia #DementiaSupport #LewyStrong